Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease.

Dineo Mpanya, Mike Sathekge, Eric Klug, Jenna Damelin, Stuart More, Bawinile Hadebe, Mariza Vorster, Nqoba Tsabedze
{"title":"Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease.","authors":"Dineo Mpanya, Mike Sathekge, Eric Klug, Jenna Damelin, Stuart More, Bawinile Hadebe, Mariza Vorster, Nqoba Tsabedze","doi":"10.3389/fnume.2023.1224905","DOIUrl":null,"url":null,"abstract":"<p><p>Gallium-68 fibroblast activation protein inhibitor [(<sup>68</sup>Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(<sup>18</sup>F)FDG] using positron emission tomography (PET). While imaging oncology patients with [<sup>68</sup>Ga]Ga-FAPI PET, incidental uptake of [<sup>68</sup>Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":" ","pages":"1224905"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440833/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2023.1224905","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Gallium-68 fibroblast activation protein inhibitor [(68Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(18F)FDG] using positron emission tomography (PET). While imaging oncology patients with [68Ga]Ga-FAPI PET, incidental uptake of [68Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
镓-68成纤维细胞活化蛋白抑制剂在心血管疾病中的正电子发射断层扫描
镓-68成纤维细胞活化蛋白抑制剂[(68Ga)Ga-FAPI]是一种新的放射性药物,其自身定位为恶性肿瘤患者的首选药物,使用正电子发射断层扫描(PET)与2-脱氧-2-[18F]氟-d-葡萄糖[2-(18F)FDG]竞争。当用[68Ga]Ga-FAPI-PET对肿瘤患者进行成像时,在心肌中检测到[68Ga]Ga-FAPI的偶然摄取。这篇综述总结了将心肌中基于FAPI的示踪剂的可视化与潜在的活动性心血管疾病联系起来的原始研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
期刊最新文献
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes. SMART-PET: a Self-SiMilARiTy-aware generative adversarial framework for reconstructing low-count [18F]-FDG-PET brain imaging. Editorial: Recent advances in radiotheranostics. αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin. Contrastive learning for neural fingerprinting from limited neuroimaging data.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1